Laboratory Co. of America Holdings (NYSE:LH) Shares Sold by Eukles Asset Management

Eukles Asset Management cut its position in Laboratory Co. of America Holdings (NYSE:LH) by 5.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,877 shares of the medical research company’s stock after selling 947 shares during the period. Laboratory Co. of America accounts for 1.6% of Eukles Asset Management’s holdings, making the stock its 18th largest position. Eukles Asset Management’s holdings in Laboratory Co. of America were worth $3,870,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. AMF Tjanstepension AB lifted its position in Laboratory Co. of America by 37.0% during the third quarter. AMF Tjanstepension AB now owns 86,026 shares of the medical research company’s stock worth $19,232,000 after buying an additional 23,221 shares in the last quarter. CWM LLC increased its stake in shares of Laboratory Co. of America by 41.0% in the 3rd quarter. CWM LLC now owns 7,107 shares of the medical research company’s stock worth $1,588,000 after acquiring an additional 2,068 shares during the last quarter. UMB Bank n.a. purchased a new position in shares of Laboratory Co. of America during the 3rd quarter worth $84,000. Exchange Traded Concepts LLC boosted its position in shares of Laboratory Co. of America by 1,962.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 990 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 942 shares during the last quarter. Finally, Birch Hill Investment Advisors LLC grew its holdings in shares of Laboratory Co. of America by 0.9% in the third quarter. Birch Hill Investment Advisors LLC now owns 140,358 shares of the medical research company’s stock valued at $31,367,000 after purchasing an additional 1,269 shares during the period. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Evercore ISI upgraded shares of Laboratory Co. of America from an “in-line” rating to an “outperform” rating and boosted their target price for the company from $260.00 to $265.00 in a report on Tuesday, January 7th. Bank of America upped their price objective on Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a report on Friday, December 13th. Barclays reduced their target price on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a research report on Friday. Robert W. Baird increased their price target on Laboratory Co. of America from $282.00 to $289.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Finally, StockNews.com raised Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Friday. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Laboratory Co. of America has an average rating of “Moderate Buy” and an average target price of $263.77.

Insider Activity

In related news, CMO Amy B. Summy sold 3,672 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $238.91, for a total value of $877,277.52. Following the sale, the chief marketing officer now owns 4,318 shares of the company’s stock, valued at $1,031,613.38. This trade represents a 45.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $239.42, for a total transaction of $239,420.00. Following the transaction, the executive vice president now owns 2,670 shares of the company’s stock, valued at $639,251.40. This trade represents a 27.25 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,383 shares of company stock worth $4,408,373. 0.85% of the stock is currently owned by company insiders.

Laboratory Co. of America Trading Down 0.6 %

NYSE LH opened at $246.18 on Monday. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $258.59. The firm has a 50 day simple moving average of $236.67 and a 200-day simple moving average of $229.85. The firm has a market cap of $20.59 billion, a price-to-earnings ratio of 27.91, a PEG ratio of 1.84 and a beta of 1.07. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44.

Laboratory Co. of America (NYSE:LH) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. Equities research analysts anticipate that Laboratory Co. of America Holdings will post 15.96 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio is currently 32.65%.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.